Companies › Abbisko Therapeutics
10 active drug programs in 18 registered trials: 10 Phase 1, 7 Phase 2, 1 Phase 3; Oncology, Other; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Pimicotinib capsule CSF1R inhibitor | CSF1R | Phase 3 | Tenosynovial Giant Cell Tumor; Healthy Subjects | Jun 2028 |
| ABSK-011 Capsules FGF19 inhibitor | FGF19 | Phase 2 | Hepatocellular Carcinoma (HCC); Healthy Participants; Advanced Liver Cancer; HCC - Hepatocellular Carcinoma | Jun 2027 |
| ABSK043 KRAS inhibitor | KRAS | Phase 2 | Non-Small Cell Lung Cancer With EGFR Mutation; Non-Small Cell Lung Cancer; Neoplasms | Jul 2027 |
| ABSK061 FGFR inhibitor | – | Phase 2 | HER2-Gastric/Gastroesophageal Junction Cancer | Nov 2029 |
| ABSK-021 | – | Phase 1 | Neoplasms | Dec 2026 |
| ABSK121-NX | – | Phase 1 | Solid Tumor | Jan 2027 |
| ABSK112 EGFR Exon20 inhibitor | EGFR | Phase 1 | Non-Small Cell Lung Cancer | Mar 2027 |
| ABSK131 MTAP inhibitor | MTAP | Phase 1 | Solid Tumors (Phase 1) | Dec 2028 |
| ABSK141 | – | Phase 1 | Solid Tumors, Adult | Dec 2028 |
| ABSK211 KRAS inhibitor | KRAS | Phase 1 | Solid Tumor (Phase I) | Dec 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06884072 | Pimicotinib capsule | Phase 1 | Healthy Subjects | Other | Jul 2025 |
| NCT07700953 | ABSK-011 Capsules | Phase 1 | Healthy Participants | Other | Aug 2026 |
| NCT06978933 | ABSK-011 Capsules | Phase 2 | HCC - Hepatocellular Carcinoma | Oncology | Dec 2026 |
| NCT04192344 | ABSK-021 | Phase 1 | Neoplasms | Oncology | Dec 2026 |
| NCT05627063 | ABSK121-NX | Phase 1 | Solid Tumor | Oncology | Jan 2027 |
| NCT06225804 | ABSK112 | Phase 1 | Non-Small Cell Lung Cancer | Oncology | Mar 2027 |
| NCT07327034 | ABSK-011 Capsules | Phase 2 | Hepatocellular Carcinoma (HCC) | Oncology | Jun 2027 |
| NCT04964375 | ABSK043 | Phase 1 | Neoplasms | Oncology | Jul 2027 |
| NCT06668103 | ABSK043 | Phase 2 | Non-Small Cell Lung Cancer With EGFR Mutation | Oncology | Dec 2027 |
| NCT04906434 | ABSK-011 Capsules | Phase 1 | Advanced Liver Cancer | Oncology | Dec 2027 |
| NCT05804045 | Pimicotinib capsule | Phase 3 | Tenosynovial Giant Cell Tumor | Oncology | Jun 2028 |
| NCT07164170 | ABSK043 | Phase 2 | Non-Small Cell Lung Cancer | Oncology | Dec 2028 |
| NCT07164170 | ABSK043 | Phase 2 | Non-Small Cell Lung Cancer | Oncology | Dec 2028 |
| NCT07417189 | ABSK141 | Phase 1 | Solid Tumors, Adult | Oncology | Dec 2028 |
| NCT07288957 | ABSK131 | Phase 1 | Solid Tumors (Phase 1) | Oncology | Dec 2028 |
| NCT06632262 | ABSK061 | Phase 2 | HER2-Gastric/Gastroesophageal Junction Cancer | Oncology | Nov 2029 |
| NCT06632262 | ABSK061 | Phase 2 | HER2-Gastric/Gastroesophageal Junction Cancer | Oncology | Nov 2029 |
| NCT07718165 | ABSK211 | Phase 1 | Solid Tumor (Phase I) | Oncology | Dec 2029 |
Jiangsu Alphamab Biopharmaceuticals DualityBio Avistone Biotechnology Nanjing Sanhome Pharmaceutical Betta Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.